Shots:

• BehaVR to receive $5M up front- ~$18M in development milestone and R&D support along with commercial & operational support fees and is eligible to receive $140M in milestone upon commercial success along with royalties on global sales of the digital therapeutic products
• The collaboration combines BehaVR's development capabilities with SDP's expertise to develop prescription therapeutics for the treatment of CNS-related disorders
• SDP has accepted to fund the development of novel VR therapies & to commercialize globally. In Jun’20- the companies signed an initial collaboration agreement to co-develop a wellness product for patients with overwhelming feelings in a social setting

 | Ref: PRNewswire | Image: PRNewswire